MuriGen Therapeutics is focused on the discovery, development and commercialisation of novel drugs
across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammatory diseases, epilepsy and thalassemia. By leveraging its unique approach to drug discovery MuriGen Therapeutics is focused on the validation of novel drug targets that have potential to provide significant benefits for researchers, health care practitioners, and patients.

MuriGen Therapeutics has developed a unique approach to generate biological information critical to
the discovery, validation, and development of new therapeutics. Its biology-based technology involves
a functional analysis of an entire mammalian genome to locate novel therapeutic entry points to treat
disease. Exploiting its proprietary discovery platform, MuriGen Therapeutics has proven the principle of
its technology using a model of thrombocytopenia.

MuriGen’s key partner is the Walter and Eliza Hall Institute (WEHI), one of the world's foremost medical
research establishments, its mission being "mastery of disease through discovery". Over many decades,
advances and discoveries at the Institute have led to significant benefits for patients throughout the world.
G-CSF was discovered at WEHI. MuriGen is based at the WEHI Biotech Centre and has access to
state-of–the-art world class facilities.

 

Murigen Pty Ltd  ABN: 80 089 736 434